Hey Cheryl, hope the recent biotech correction has not
taken you out of anything in which you consider yourself
an investor...these are difficult times--though not as bad
as last fall for me.
Okay, back on topic:
Pathol Biol (Paris) 2000 Feb;48(1):80-6
Why are growth factors important in oligodendrocyte physiology?
Dubois-Dalcq M, Murray K
Unite de Neurovirologie et Regeneration du Systeme Nerveux,
Institut Pasteur, Paris, France.
Recent studies in chicken, rodents and transgenic mice have
provided new insight on the nature of factors essential to
oligodendrocyte development. Here we first review how sonic
hedgehog (shh) graded signalling induces emergence of
oligodendrocytes in the embryonic spinal cord from birds to
man. We then discuss the way in which thyroid hormone
successively signals different thyroid receptors to control
fate determination, growth and differentiation in the
oligodendrocyte lineage. Platelet-derived growth factor
(PDGF) is a potent regulator of oligodendrocyte progenitor
(OP) migration and proliferation, while insulin-like growth
factor 1 (IGF-1) acts both on neurons and myelin-forming
cells to promote myelination. The balance between OP
proliferation and differentiation appears to be controlled
by different sets of growth factors locally synthesized in
the central nervous system (CNS) as well as glutamate.
In experimental models of multiple sclerosis (MS), the
neuregulin isoform glial growth factor 2, IGF-1 and some
neurotrophins can promote remyelination after an episode of
inflammatory demyelination. A future challenge is to
determine how to induce multipotential neural precursors to
generate migratory OP and enhance the remyelination process
in the adult CNS.
PMID: 10729915, UI: 20194108
Also, not to rub too much salt in old wounds...but CNSI has the all the rights to Cerestat (Apiganel).
Now even though this failed in phase III, and we see here...
A 4.5-mg intravenous bolus of aptiganel HCl followed by
infusion of 0.75 mg/h for 12 hours is a tolerable dose that
can produce plasma drug concentrations shown to be
neuroprotective in animal models. However, increases
in systolic blood pressure and an excess of CNS effects were
both observed at this dose.
(Stroke 1999 Oct;30(10):2038-42)
Is this the sort of molecule that might be rejiggered and
tried again someday? I never did my DD on SEPR, but when the
stock went up today on good news, I thought--what about all
the old failed molecules out there. Can the one isomer be
tested again?
Just wondering. If CNSI has to sell off the pieces, so be
it--but if this were an IPO starting fresh, how could you
not buy it at this marketcap? Not a lot of success before
now, but they have experience, the pain molecule in phase
II--and the GGF patents. Every dog has his day, seems like
cnsi deserves, and is certainly due, for some success. And
I'm not even sure cnsi deserves to be lumped in with other
the other otc.bb dogs.
I think the downside is limited to the backlash from
the sector getting hammered--and the stock seems to have
stopped falling here at 1 5/8. Recently I've been shook up
by the biotech correction, but I actually bought a little
more cnsi yesterday when I found myself with extra cash
between some crummy trades.
I'd sure like to know if BVF Lampert is the reason this
fell a buck from the upper $2's, or if this was just
sagging with the sector. |
